The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 30, 2021

Filed:

Oct. 02, 2020
Applicant:

Impel Neuropharma, Inc., Seattle, WA (US);

Inventors:

John D. Hoekman, Seattle, WA (US);

Kelsey H. Satterly, Seattle, WA (US);

Stephen B. Shrewsbury, Fallbrook, CA (US);

Scott Youmans, Bothell, WA (US);

Christopher Fuller, Seattle, WA (US);

Assignee:

Impel Neuropharma, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 25/06 (2006.01); A61K 9/00 (2006.01); A61M 11/00 (2006.01); A61M 11/02 (2006.01); A61M 15/00 (2006.01); A61K 31/48 (2006.01); A61K 31/522 (2006.01); A61K 47/26 (2006.01); A61M 15/08 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0043 (2013.01); A61K 31/48 (2013.01); A61K 31/522 (2013.01); A61K 47/26 (2013.01); A61M 11/002 (2014.02); A61M 11/02 (2013.01); A61M 15/002 (2014.02); A61M 15/0028 (2013.01); A61M 15/0065 (2013.01); A61M 15/08 (2013.01); A61P 25/06 (2018.01);
Abstract

Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (C) of at least 750 pg/ml, (b) with a mean time to C(T) of DHE of less than 45 minutes, and (c) a mean plasma AUCof DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.


Find Patent Forward Citations

Loading…